Solvonis wins second U.S. patent to deepen PTSD therapy IP

Solvonis Therapeutics ( (GB:SVNS) ) has provided an update.

Solvonis Therapeutics has secured a second U.S. patent covering a chemically distinct monoamine modulator series from its proprietary post-traumatic stress disorder discovery programme, extending protection over compounds that target serotonin, dopamine and noradrenaline transporters. The composition-of-matter patent, which runs to 2043 subject to standard conditions, is regarded as particularly valuable because it protects the molecules themselves in a PTSD market where more than 20 million patients across major Western markets have limited pharmacological options.

The new patent follows closely on recent milestones for the PTSD programme, including the selection of SVN-114 as lead candidate and the grant of another U.S. patent for a separate chemical series, significantly expanding Solvonis’ protected chemistry estate. Management argues that securing patents across two distinct monoamine modulator series not only strengthens the long-term value of its PTSD franchise but also enhances lifecycle management and follow-on development options, positioning the company to benefit from rising strategic interest in next-generation psychiatric treatments.

In the context of increasing deal activity in the sector, such as large acquisitions focused on next-generation PTSD and psychiatric therapies, the reinforced intellectual property is intended to support Solvonis’ negotiations with potential partners and investors. The broader platform, spanning multiple novel chemical series, underlines the company’s ambition to build a diversified CNS pipeline beyond a single lead asset and could improve its competitive standing in a rapidly evolving neuropsychiatric therapeutics landscape.

The most recent analyst rating on (GB:SVNS) stock is a Hold with a £0.26 price target. To see the full list of analyst forecasts on Solvonis Therapeutics stock, see the GB:SVNS Stock Forecast page.

Spark’s Take on SVNS Stock

According to Spark, TipRanks’ AI Analyst, SVNS is a Neutral.

The score is held down primarily by weak fundamentals (zero revenue in 2024, ongoing losses, and continued cash burn), despite the benefit of a low-debt balance sheet. Technical indicators are supportive (price above key moving averages with positive MACD), but missing P/E and dividend yield data limits valuation assessment.

To see Spark’s full report on SVNS stock, click here.

More about Solvonis Therapeutics

Solvonis Therapeutics plc is a London-headquartered biopharmaceutical company focused on developing small-molecule therapeutics for high-burden central nervous system disorders, with a particular emphasis on addiction and psychiatric conditions. Listed on the main market of the London Stock Exchange, the company’s pipeline includes lead programmes for Alcohol Use Disorder and Post-Traumatic Stress Disorder, supported by proprietary discovery platforms targeting key neurotransmitter systems.

Its lead asset, SVN-001, is in Phase 3 trials in the UK for severe Alcohol Use Disorder, while SVN-002 is being prepared for a Phase 2b study in the U.S. in moderate-to-severe cases. Solvonis is also advancing its PTSD discovery programme, where lead compound SVN-114 is designed to modulate brain signalling systems linked to emotional processing and social behaviour, underpinning the company’s broader ambition to expand into additional addiction and depressive disorder indications.

The company leverages a dedicated compound library and a capital-efficient development model to drive early-stage CNS innovation. This integrated approach, combined with a focus on partnering opportunities, is intended to deliver sustained value by bringing novel psychiatric and addiction treatments to a large, underserved global patient population.

Average Trading Volume: 34,880,260

Technical Sentiment Signal: Sell

Current Market Cap: £17.7M

See more data about SVNS stock on TipRanks’ Stock Analysis page.